"Australian Medicines Regulator Sounds Alarm on Diabetes and Weight Loss Drugs. In a move that will send shockwaves through the healthcare community, Australia's Therapeutic Goods Administration (TGA) has issued warnings for several popular type 2 diabetes and obesity treatments, including Ozempic and Mounjaro. The regulator has linked these medications to a rare but potentially devastating eye disorder known as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), which can cause blindness. With 36 reported cases of the condition, the TGA's decision to update product information with a warning is a stark reminder of the potential risks associated with these widely prescribed medications, and raises important questions about patient safety and the long-term consequences of using these treatments."
TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorderFollow our Australia news live blog for latest updatesGet our breaking news email, free app or daily news podcastAustralia’s medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments – including Ozempic and Mounjaro – over the potential to cause a “rare but severe” eye disorder that could lead to blindness.The Therapeutic Goods Administration’s (TGA) warning came after several GLP-1 RA medicines marketed in Australia as Ozempic, Wegovy and Mounjaro, among other products, were linked to 36 cases of the condition. Continue reading...
